Last reviewed · How we verify

NCT03055247: XCGD-MOBI

Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD

Recruiting now Phase 2 Last updated 18 September 2025
What this trial tests

Phase 2 trial testing Ibuprofen in Chronic Granulomatous Disease X-linked (X-CGD) in 3 participants. Currently enrolling.

Timeline
6 November 2015
Primary endpoint
13 July 2023
18 July 2026

Quick facts

Lead sponsorIRCCS San Raffaele
PhasePhase 2
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment3
Start date6 November 2015
Primary completion13 July 2023
Estimated completion18 July 2026
Sites2 locations across Italy

Drugs / interventions tested

Conditions studied

Sponsor

IRCCS San Raffaele — full company profile →

Who can join

Adults 18 to 45, male only, with Chronic Granulomatous Disease X-linked (X-CGD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase II exploratory study conducted to evaluate the safety and efficacy of the combination of Ibuprofen, G-CSF and Plerixafor as stem cell mobilization regimen in patients affected by X-CGD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ibuprofen

Trials testing the same drug.

Other IRCCS San Raffaele trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03055247.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing